HF
AVBP icon

HRT Financial’s ArriVent BioPharma AVBP Stock Holding History

HRT Financial’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Sell
47,053
-6,371
-12% -$144K ﹤0.01% 2007
2025
Q4 		$1.07M Buy
+53,424
New +$1.11M ﹤0.01% 1668
2025
Q3 		– Sell
-25,346
Closed -$551K – 3811
2025
Q2 		$551K Buy
+25,346
New +$526K ﹤0.01% 1557

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HRT Financial's AVBP Position: Q1 2026 in Review

HRT Financial reduced its ArriVent BioPharma (AVBP) stake by 12% in Q1 2026, selling an estimated $144K and leaving 47,053 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2007.

HRT Financial first reported a position in AVBP in Q2 2025 and has held it in 3 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • HRT Financial held 47,053 shares of ArriVent BioPharma worth $1.08M as of Q1 2026.
  • HRT Financial sold 6,371 ArriVent BioPharma shares in Q1 2026, an estimated $144K.
  • ArriVent BioPharma made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #2007 holding.
  • HRT Financial first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 3 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.